STOKE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.84 USD | -6.17% |
|
+4.81% | +179.56% |
Presenter SpeechEdward Tenthoff (Analysts)My name is Ted Tenthoff. I'm a senior biotech analys...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Companyâs initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Calendar
04/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.81
USD
Average target price
22.14
USD
Spread / Average Target
+40.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +179.56% | 824M | |
| +63.08% | 62.59B | |
| -2.02% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +12.34% | 26.21B | |
| -21.88% | 19.09B | |
| +3.49% | 13.08B | |
| +25.39% | 12.26B | |
| +27.30% | 12.05B |
- Stock Market
- Equities
- STOK Stock
- News Stoke Therapeutics, Inc.
- Transcript : Stoke Therapeutics, Inc. Presents at Piper Jaffray 31st Annual Healthcare Conference, Dec-04-2019 11
